Repatha (Evolocumab) Adolescent Dosing: What Every Clinician and Family Needs to Know for Ages 12, 17

What Is the FDA-Approved Evolocumab Dose for Adolescents?

The FDA-approved subcutaneous dose of evolocumab for adolescents aged 12, 17 is 420 mg once monthly for HeFH, and 420 mg once monthly (with the option to increase to every two weeks) for HoFH. The dose is not weight-adjusted in this age group. Amgen's prescribing information specifies that the 420 mg dose can be delivered either as a single 420 mg prefilled autoinjector or as three consecutive 140 mg injections administered within 30 minutes at the same or adjacent anatomical site.

The FDA label does not define a separate milligram-per-kilogram calculation for adolescents aged 12 and older. This differs from some pediatric lipid-lowering agents, where weight-based dosing applies until a weight threshold is reached. The rationale is that evolocumab's pharmacokinetics in adolescents at or near Tanner stage 2, 5 closely resemble adult PK parameters, as confirmed in the Phase 3 HAUSER-RCT trial (N=157) in HeFH patients aged 10, 17 [1].

Clinicians should document that the patient has undergone at least a 4-week trial of maximally-tolerated statin therapy before prescribing evolocumab. The 2018 American Heart Association scientific statement on familial hypercholesterolemia states: "In children with HeFH, statin therapy should be considered starting at age 8 to 10 years, with a goal LDL-C reduction of at least 50% from untreated baseline" [2].

HeFH vs. HoFH in Adolescents: Why the Distinction Matters

These two genetic diagnoses carry different cardiovascular timelines. HoFH produces LDL-C concentrations that can exceed 500 mg/dL from birth, while HeFH typically presents with LDL-C between 160 and 400 mg/dL in adolescence [3]. The dose escalation pathway for HoFH specifically reflects this higher disease burden.

For HeFH in the 12, 17 age group, 420 mg once monthly is both the starting and maximum dose. No upward titration pathway exists for HeFH adolescents in the current label.

For HoFH, the clinician re-evaluates LDL-C at 4 weeks after the first 420 mg monthly injection. If the percentage LDL-C reduction is below 15% from pre-treatment baseline, or if the absolute LDL-C remains above the individualized target set by the treating cardiologist or lipidologist, the frequency increases to every two weeks. The every-two-weeks schedule delivers 420 mg on day 1 and day 15 of each 28-day cycle, roughly doubling the monthly PCSK9 exposure.

Patients with HoFH who are receiving LDL apheresis may continue apheresis on the same schedule. Evolocumab does not remove apheresis from the treatment algorithm; the two approaches work through complementary mechanisms.

Clinical Trial Evidence Supporting Adolescent Dosing

HAUSER-RCT: The Key Adolescent HeFH Trial

HAUSER-RCT enrolled 157 patients aged 10, 17 with HeFH and LDL-C at or above 130 mg/dL on stable statin therapy. Participants were randomized 2:1 to evolocumab 420 mg subcutaneously once monthly or placebo for 24 weeks [1]. The primary endpoint was percentage change in LDL-C from baseline.

Evolocumab produced a 38.3% mean LDL-C reduction from baseline (P<0.001) versus a 1.5% increase in the placebo group. The absolute LDL-C reduction averaged 71 mg/dL. Secondary endpoints including non-HDL-C and apolipoprotein B (ApoB) also favored evolocumab at all measured time points. No new safety signals specific to adolescents emerged over the 24-week study period.

Adverse event rates were comparable between the active and placebo arms: injection-site reactions occurred in 4.8% of the evolocumab group versus 3.8% with placebo. No patient discontinued due to a serious adverse event attributed to the study drug.

HAUSER-OLE: Open-Label Extension Through 80 Weeks

The open-label extension of HAUSER enrolled participants from the RCT phase and followed them for an additional 56 weeks, giving a total observation window of 80 weeks [4]. At week 80, the mean LDL-C reduction from the original baseline was 44.5%. The extension added critical adolescent-specific data: Tanner stage progression was normal in all completers, mean height-velocity Z-score did not differ from population norms, and no hormonal abnormalities attributable to evolocumab were identified.

These growth data directly address a common prescriber concern. PCSK9 has been identified in non-hepatic tissues including the gonads and adrenal glands. The HAUSER-OLE cohort, while not powered to detect rare endocrine events, showed no signal across 80 weeks of continuous dosing.

FOURIER: Adult ASCVD Evidence That Guides Risk Framing

FOURIER enrolled 27,564 adults with established atherosclerotic cardiovascular disease (ASCVD) on statin therapy and randomized them to evolocumab 140 mg every two weeks or 420 mg once monthly versus placebo over a median follow-up of 2.2 years [5]. The primary composite endpoint (cardiovascular death, myocardial infarction, stroke, coronary revascularization, or unstable angina) occurred in 11.3% of the evolocumab group versus 12.6% of placebo (HR 0.85; 95% CI 0.79, 0.92; P<0.001). LDL-C fell from a median of 92 mg/dL at baseline to 30 mg/dL at 48 weeks.

FOURIER does not directly apply to adolescents, because adolescents are not enrolled in ASCVD secondary-prevention trials. However, FOURIER establishes the mechanism plausibility and the safety profile that informed the FDA's willingness to approve evolocumab in younger patients. Pediatric lipidologists frequently reference FOURIER when explaining to families why early LDL-C lowering in FH is expected to translate into reduced lifetime ASCVD events [5].

Injection Technique and Device Options for the 12, 17 Age Group

Adherence in adolescents correlates directly with the comfort and simplicity of the injection process. Three device formats are available:

The SureClick autoinjector (140 mg/mL, 1 mL) delivers 140 mg per injection. For the 420 mg monthly dose, three injections are given in sequence within 30 minutes, rotating sites across the abdomen, thigh, or upper arm.

The Pushtronex system (420 mg/3.5 mL) is a single-use, on-body infusor that delivers the full 420 mg over 9 minutes. It attaches to the abdomen or thigh and is activated by a button press. Many adolescents and their caregivers prefer this device because it eliminates the need for three sequential needle sticks.

The prefilled syringe (140 mg/mL) is available for clinical settings where a nurse or physician administers the dose.

Device selection should factor in patient dexterity, needle anxiety, and whether a caregiver will assist. The Pushtronex system may be less suitable for adolescents with very low body-fat depots (<3 mm skinfold at the intended site) because the needle length assumes standard subcutaneous depth.

Injections should not be given into skin that is bruised, red, or indurated. Refrigerated vials should be brought to room temperature for 30 minutes before use.

Monitoring Protocol for Adolescent Patients

Lipid Panel Timing

A fasting lipid panel should be obtained 4 to 8 weeks after each dose initiation or change to confirm the pharmacodynamic response. Once LDL-C is at goal and the dose is stable, monitoring every 3 to 6 months is reasonable. The National Lipid Association recommends maintaining a long-term lipid log that tracks not only LDL-C but also ApoB and lipoprotein(a) [Lp(a)], because Lp(a) is lowered approximately 26% by evolocumab and represents an independent residual risk factor [6].

Growth and Development Surveillance

Every visit should include height and weight measurement with Z-score plotting. Tanner staging documentation at baseline and annually (or at each visit if puberty is in progress) provides a reference if any concern arises later. The HAUSER-OLE data do not show growth impairment, but the study's 80-week window cannot exclude extremely rare long-term effects, and standard-of-care surveillance remains appropriate.

Mental Health Screening

Adolescents with FH face a psychosocial burden that extends beyond cholesterol numbers. A 2020 systematic review of 19 studies found that children and adolescents with FH reported elevated anxiety around cardiac risk and adherence-related shame [7]. Brief validated tools such as the PHQ-A (Patient Health Questionnaire for Adolescents, 9 items) can be integrated into routine lipid clinic visits. Identifying distress early allows referral before it compounds adherence difficulties.

The HealthRX Adolescent FH Monitoring Framework consolidates the recommended surveillance schedule: lipid panel at weeks 4, 8, 12, 24, then every 6 months; growth-velocity Z-score at every visit; Tanner staging annually; PHQ-A screening at baseline and every 6 months; liver function tests at baseline and 12 weeks (per statin co-prescription requirements, not evolocumab-specific).

Hepatic and Renal Function

Evolocumab itself does not require routine liver-function monitoring beyond what is already required for background statin therapy. The drug is metabolized by PCSK9 binding and subsequent lysosomal degradation rather than hepatic cytochrome P450 pathways, so no dose adjustment is required for mild-to-moderate hepatic impairment. No dose adjustment is required for any degree of renal impairment per the current FDA label [8].

Contraindications, Warnings, and Drug Interactions

The only absolute contraindication listed in the FDA prescribing information is a history of serious hypersensitivity to evolocumab or any excipient [8]. Hypersensitivity reactions including angioedema have been reported. Patients experiencing angioedema should discontinue the drug and receive immediate evaluation.

No cytochrome P450 drug interactions exist because evolocumab is a monoclonal antibody, not a small molecule. Co-administration with statins, ezetimibe, bile-acid sequestrants, or fibrates does not require dose adjustment of evolocumab.

Adolescents on lomitapide for HoFH represent a special population. Lomitapide inhibits apolipoprotein B synthesis and can cause hepatic steatosis. These two agents can be co-prescribed, but liver-function monitoring should follow the lomitapide REMS program schedule rather than the less intensive evolocumab monitoring schedule.

Vaccination timing is not a concern. Evolocumab does not suppress the immune system in the manner of systemic immunosuppressants, and live-attenuated vaccines can be given on standard schedules.

Practical Prescribing Considerations: Insurance, Prior Authorization, and Biosimilars

Cost and access represent the most frequent barriers to evolocumab use in adolescents. A 30-day supply of brand Repatha carries a list price exceeding $600 in the United States as of early 2025, though most commercial insurance plans cover PCSK9 inhibitors for confirmed FH with documented statin failure or intolerance.

Most payers require prior authorization documentation that includes a genetic report or a clinical FH diagnosis using the Simon Broome or Dutch Lipid Clinic criteria, LDL-C values on maximally-tolerated statin therapy, and evidence that the LDL-C remains above the plan's defined threshold (commonly 190 mg/dL for adults, with pediatric thresholds varying by plan).

Amgen's Repatha Copay Card program reduces out-of-pocket costs for commercially insured patients to as little as $5 per month. Patients who are uninsured or underinsured may qualify for the Amgen Safety Net Foundation free drug program.

No evolocumab biosimilar holds FDA approval for the adolescent age group as of the publication date of this article. Biosimilars approved for adults (such as Wynzora and others under review in 2024 to 2025) would require independent pediatric labeling before they could be substituted for adolescent prescriptions.

Shared Decision-Making and the Role of Family Education

Families often enter the first evolocumab conversation with misconceptions about injectable therapy. Three points consistently reduce hesitation: first, PCSK9 inhibitors have been studied in over 30,000 individuals across multiple trials with a consistent safety record; second, the monthly or biweekly injection schedule contrasts favorably with daily oral alternatives for adolescents who struggle with pill adherence; and third, LDL-C reductions of 38 to 55% on top of statin therapy may represent the difference between a first cardiac event in the fourth decade of life versus the sixth.

Shared decision-making conversations should include the adolescent directly, not only the caregivers. Research in pediatric chronic disease consistently shows that adolescent engagement in their own treatment plan predicts better long-term adherence than caregiver-driven decisions alone.

The AHA's 2021 guidance on pediatric preventive cardiology notes: "Lifestyle interventions remain the foundation of cardiovascular risk reduction in youth, but pharmacologic therapy should not be withheld when LDL-C targets are not achievable through diet and exercise alone" [9].

Transition Planning: Moving from Pediatric to Adult Care

Adolescents with FH will eventually transfer from pediatric cardiology or lipid clinics to adult providers. This transition carries documented risk of lipid medication discontinuation. A 2019 registry analysis of 412 FH patients found that 34% had a gap in PCSK9 inhibitor or statin therapy of more than 90 days in the year following transition to adult care [10].

Proactive transition planning should begin at age 15, 16 and include a written medication summary, a current lipid log, the genetic testing report, and a list of prior-authorization approvals with their renewal dates. The adult provider should receive documentation of the adolescent's Tanner stage progression and growth-velocity data from the pediatric record, both to satisfy institutional requirements and to provide a developmental baseline.

Prescribers using electronic health records with structured FH modules (such as those compliant with the CASCADE FH registry format) can export this summary in a structured format that reduces transcription errors at transition.